New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 967-977

  Mekaj, Ymer H ^a,b   Mekaj, Agon Y ^a   Duci, Shkelzen B ^a   Miftari, Ermira I ^c  

^a UNIVERSITY OF PRISHTINA   (Serbia)

^b National Blood Transfusion Center of Kosovo   (Serbia)

^c UNIVERSITY CLINICAL CENTER OF KOSOVO   (Serbia)

Author keywords

Direct IIa and Xa inhibitors; Novel oral anticoagulants; Venous thromboembolism; Vitamin K antagonist

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLARITHROMYCIN; DABIGATRAN; DABIGATRAN ETEXILATE; DRONEDARONE; EDOXABAN; ENOXAPARIN; ERYTHROMYCIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PHENYTOIN; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CHRONIC KIDNEY DISEASE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SELECTIVITY; EMBOLISM; FOOD; FOOD DRUG INTERACTION; HEART INFARCTION; HUMAN; INTRACARDIAC THROMBOSIS; LIVER DISEASE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; OCCLUSIVE CEREBROVASCULAR DISEASE; PHARMACODYNAMICS; SINGLE DRUG DOSE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM;

EID: 84933500385     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S84210     Document Type: Article

References (81)

1. Goldhaber SZ. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol. 1992;19(2):246-247.
2. Gómez-Outes A, Suárez-Gea ML, Calvo-Rojas G, et al. Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol. 2012;9(2):83-104.
3. Holy EW, Beer JH. Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Med. 2013;16:103-114.
4. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625-651.
5. Campbell HA, Roberts WL, Smith WK, Link KP. Studies of the hemorrhagic sweet clover disease. I. The preparation of hemorrhagic concentrates. J Biol Chem. 1940;136:47-55.
6. Ferlund P, Stenflo J, Roepstorff P, Thomsen J. Vitamin K and the biosynthesis of prothrombin. V. Gamma-carboxyglutamic acids, the vitamin K-dependent structures in prothrombin. J Biol Chem. 1975;250(15):6125-6133.
7. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S-469S.
8. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem. 1982;257(19):11210-11212.
9. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol. 1988;25(1):1-7.
10. Ickx BE, Steib A. Perioperative management of patients receiving vitamin K antagonists. Can J Anaesth. 2006;53(6 Suppl):S113-S122.
11. Klauser W, Dütsch M. Partial management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg. 2013;97(3):189-197.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
13. da Silva RM. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovasc Hematol Agents Med Chem. 2014;12(1):3-8.
14. Gayle JA, Kaye AD, Kaye AM, Shah R. Anticoagulants: newer ones, mechanisms, and perioperative updates. Anesthesiol Clin. 2010;28(4):667-679.
15. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-399.
16. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.
17. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723.
18. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669-676.
19. Artang R, Rome E, Nielsen JD, Vidaillet HJ. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013;112(12):1973-1979.
20. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risk in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157-164.
21. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
22. Schulman S, Kakkar AK, Goldhaber SZ, et al. RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772.
23. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
24. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(5):570-580.
25. Hoffman R, Brenner B. The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol. 2012;25(3):351-360.
26. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65(16):1520-1529.
27. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-3939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.
28. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY-59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421.
29. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.
30. Weinz C, Radke M, Sshmreer R. In vitro metabolisem of BAY 5979-39 and oral, direct factor Xa inhibitor. Drug Metab Rev. 2004;36(Supp 1):98.
31. Eriksson BI, Borris LC, Dahl OE, et al; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114(22):2374-2381.
32. Turpie AG, Fisher WD, Bauer KA, et al; OdiXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3(11):2479-2486.
33. Frost C, Song Y, Barrett YC, et al. A randomized direct comprasion of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014;6:179-187.
34. Bayer Pharma AG. Xarelto (Rivaroxaban) Xarelto®: Summary of Product Characteristics-EU. 2013. Available from: http://www.xarelto.com/en/information-on-xarelto/summary-of-product-characteristics/. Accessed May 1, 2014.
35. Mega JL, Braunwald E, Wiviott SD; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19.
36. Halabi A, Kubitza D, Zuehlsdorf M. Effect of hepatic impairment on the pharmacokinetics and tolerability of rivaroxaban, and oral, direct factor Xa inhibitor. J Thromb Haemost. 2007;5(Suppl 2):P-M-635.
37. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
38. Hirschl M, Kundi M. New oral anticoagulants in the treatment of acute venous thromboembolism-a systematic review with indirect comparisons. Vasa. 2014;43(5):535-564.
39. EINSTEIN-PE Investigators. Oral rivaroxaba for the treatment symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1897.
40. Gallego P, Roldán V, Lip GY. Novel oral anticoagulants in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2014;19(1):34-44.
41. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
42. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Investig Drugs. 2008;9(9):1020-1033.
43. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-1549.
44. Daiichi Sankyo Europe GmbH. First market approval in Japan for LIXIANA (Edoxaban) [press release]. Tokyo: Daiichi Sankyo Europe GmbH; 2011 [April 22]. Available at: http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/005784.html. Accessed December 1, 2013.
45. O'Riordan M (9 January 2015). FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention. Medscape. Available from: http://www.medscape.com/viewarticle/837837. Accessed January 10, 2015.
46. Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular trial fibrillation. Eur J Clin Pharmacol. 2014;70(11):1339-1351.
47. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121(13):1523-1532.
48. Fuji T, Fujita S, Tachibana S, Kawai Y. Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthoplasty. Blood. 112:34 (abstract).
49. Weitz JI, Connolly SJ, Patel I. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-641.
50. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, et al. Edoxapan versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
51. Fuji T, Wang CJ, Fujita S, et al. Edoxaban versus enoxaparin for thrombophylaxis after total knee arthoplasty: the STARS E-3 trial. Pathophysiol Haemost Thromb. 2010;37:A20 (OC297).
52. Fuji T, Fujita S, Kawai Y, et al. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thromb J. 2015;13(1):6.
53. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Edoxaban versus warfarin for stroke prevention in non-valvular trial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2015;39(2):149-154.
54. Cohen AT, Spiro TE, Büller HR, et al. Rivoroxaban for thrombophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523.
55. Cowell RP. Direct oral anticoagulants: integration into clinical practice. Postgrad Med J. 2014;90(1067):529-539.
56. Yates J, Choudhry M, Keys G. A case report describing a suspected riraroxaban hypersensibility reaction in a surgical patient. J Clin Pharm Ther. 2013;38(2):159-161.
57. European Medicines Agency. Pradaxa®-Summary of Product Characteristics. 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed March 13, 2012.
58. European Medicines Agency. Eliquis®-Summary of Product Characteristics. 2014. Available from: Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed June 2, 2013.
59. SAVAYSA™ (edoxaban) tablets [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2015. Available from: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed February 9, 2015.
60. Tadros R, Shakib S. Warfarin-indications, risks and drug interactions. Aust Fam Physician. 2010;39(7):476-479.
61. Abadi S, Einarson A, Koren G. Use of warfarin during pregnancy. Can Fam Physician. 2002;484(4):695-697.
62. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008;42(4):523-532.
63. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464-470.
64. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338(1):372-380.
65. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111(10):4871-4879.
66. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448-458.
67. O'Connell JE, Stassen LF. New oral anticoagulants and their implications for dental patients. J Ir Dent Assoc. 2014;60(3):137-143.
68. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of riraroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218-226.
69. Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor. J Clin Pharmacol. 2013;53(3):249-255.
70. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10.
71. Eikelboom JW, Connolly SJ, Brueckmann M; RE-ALGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-1214.
72. Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J. 2014;12:24.
73. Brighton T. New oral anticoagulant drugs-mechanisms of action. Aust Prescr. 2010;33:38-41.
74. Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175-189.
75. Kepplinger J, Barlinn K, Gehrisch S, et al. Are the recommendations for the emergency management of acute ischemic stroke patients on novel oral anticoagulants sufficient? Stroke. 2014;45:ATMP57.
76. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2012;103(6):1116-1127.
77. Blann AD. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. Br J Biomed Sci. 2014;71(4):158-167.
78. Samama MM, Contant K, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379-387.
79. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138-143.
80. Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) receives FDA breakthrough therapy designation [press release]. Ridgefield, CT: Boehringer Ingelheim; 2014 [June 26]. Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/06-26-14-boehringer-ingelheim-investigational-antidote-pradaxa-dabigatran-etexilate-mesylate-fda-breakthrough-therapy-designation.html. Accessed July 26, 2014.
81. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451.